MedTrace Logo

Preoperative Hemogram Parameters and BRAF Molecular Test Detected by Bethesda 3 Cytology.

NCT06539702 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2024-08-06

No results posted yet for this study

Summary

The main hypothesis of this study is that preoperative hemogram parameters can be used as biomarkers for malignancy in patients with thyroid nodule Bethesda 3 cytology.

The secondary hypothesis is that BRAF molecular testing has a high predictive value in predicting malignancy in patients with thyroid nodule Bethesda 3 cytology.

Primary outcome: Preoperative hemogram parameters. Secondary outcome: BRAF positivity.

Conditions

  • Blood Platelet Disorder
  • BRAF V600E
  • Thyroid Nodule
  • Cytologic Atypia

Sponsors & Collaborators

  • Saglik Bilimleri Universitesi

    lead OTHER

Principal Investigators

  • Ugur Kesici, Assoc.Prof. · Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-07-20
Primary Completion
2024-08-06
Completion
2024-08-15

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06539702 on ClinicalTrials.gov